TECX
Tectonic Therapeutic, Inc. Common StockTECX
TECX
About: Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
400% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 5 (+4) [Q3]
325% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 4
148% more capital invested
Capital invested by funds: $88.3M [Q2] → $219M (+$130M) [Q3]
30% more funds holding
Funds holding: 40 [Q2] → 52 (+12) [Q3]
12.58% more ownership
Funds ownership: 36.39% [Q2] → 48.96% (+12.58%) [Q3]
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$65
57%
upside
Avg. target
$71
72%
upside
High target
$79
91%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Raymond James Danielle Brill 43% 1-year accuracy 6 / 14 met price target | 57%upside $65 | Outperform Initiated | 20 Nov 2024 |
Wells Fargo Tiago Fauth 50% 1-year accuracy 11 / 22 met price target | 91%upside $79 | Overweight Maintained | 12 Nov 2024 |
Leerink Partners David Risinger 22% 1-year accuracy 2 / 9 met price target | 67%upside $69 | Outperform Maintained | 11 Nov 2024 |
Financial journalist opinion
Positive
Seeking Alpha
2 weeks ago
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension, showing promise in early clinical trials. TX45's extended half-life and monthly dosing address limitations of native relaxin, positioning it as a potential best-in-class therapeutic. With favorable phase 1a data and ongoing phase 1b and 2 trials, Tectonic's TX45 could become a market leader, potentially attracting interest from potential biopharma acquirers.
Neutral
GlobeNewsWire
1 month ago
Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024
WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024 from 4:00 PM to 6:00 PM ET. To register, click here .
Neutral
GlobeNewsWire
1 month ago
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Piper Sandler 36th Annual Healthcare Conference being held in New York on December 3-5, 2024.
Neutral
GlobeNewsWire
2 months ago
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
WATERTOWN, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced detailed results from the Phase 1a clinical trial of its lead asset, TX45, a long-acting, Fc-relaxin fusion protein. The poster will be presented at the American Heart Association (AHA) Scientific Sessions on November 16, 2024 from 3-4pm EST in Chicago, Illinois. Favorable topline results from the TX45 Phase 1a clinical trial were announced on September 19, 2024, along with the dose selection for the TX45 APEX Phase 2 trial that is currently underway in patients with PH-HFpEF.
Neutral
GlobeNewsWire
3 months ago
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
American Heart Association (AHA) poster to be presented on November 16, 2024 American Heart Association (AHA) poster to be presented on November 16, 2024
Positive
Seeking Alpha
3 months ago
Tectonic Therapeutic: Interesting CV Disease Drug Developer
Tectonic Therapeutic's lead candidate TX45 showed positive phase 1 results for Group 2 Pulmonary Hypertension, driving the stock up over 100% in September. TX45 is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, offering potential therapeutic benefits for hypertension and heart failure with preserved ejection fraction (HFpEF). Tectonic has a solid financial position with a market cap of $551mn, $185mn in cash reserves, and a cash runway extending into 2027.
Neutral
GlobeNewsWire
4 months ago
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial
Neutral
InvestorPlace
4 months ago
TECX Stock Earnings: Tectonic Therapeutic Misses EPS for Q2 2024
Tectonic Therapeutic (NASDAQ: TECX ) just reported results for the second quarter of 2024. Tectonic Therapeutic reported earnings per share of -$4.34.
Neutral
GlobeNewsWire
5 months ago
Tectonic Therapeutic to Participate in September Investor Conferences
WATERTOWN, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will present at the 2024 Wells Fargo Healthcare Conference being held in Boston on September 4-6, 2024 and participate in the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on September 4-6, 2024.
Neutral
GlobeNewsWire
5 months ago
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024 Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024 Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 million Cash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”, or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced its financial results for the second quarter ending June 30, 2024, and provided an overview of recent business highlights.
Charts implemented using Lightweight Charts™